---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-222808"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-05-14T11:32:05+00:00"
generated_at: "2026-05-14T11:37:03.009432+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete

## Summary
- U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.
- Net loss $22.4M ($1.02 basic loss per share) vs $23.5M loss in Q1 2025.
- Cash $91.2M as of Mar 31, 2026; expects liquidity to fund operations into late Q3 2026.
- Completed Phase 3 XPORT-EC-042 enrollment in endometrial cancer; topline data expected mid-2026.
- Phase 3 SENTRY myelofibrosis results accepted for late-breaking oral at ASCO on June 2.

## SEC filing metadata
- accession: 0001193125-26-222808
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-05-14T11:32:05+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/0001193125-26-222808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/kpti-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-222808
- JSON: https://secwatch.observer/filing/0001193125-26-222808.json
- Plain text: https://secwatch.observer/filing/0001193125-26-222808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.